Side-by-side comparison of AI visibility scores, market position, and capabilities
Largest US pharmaceutical distributor with $308.9B FY2024 revenue; thin-margin distribution triopoly with Cencora and Cardinal Health; US Oncology Network (1,700+ oncologists) is highest-margin segment.
McKesson Corporation is the largest pharmaceutical distributor in North America and a leading healthcare services company, founded in 1833 in New York City by John McKesson and Charles Olcott and now headquartered in Irving, Texas, trading on NYSE (MCK). The company reported approximately $308.9 billion in revenues for fiscal year 2024 (ending March 31, 2024) under CEO Brian Tyler, making it one of the highest-revenue companies in the United States—though the vast majority of revenues represent pass-through pharmaceutical product costs distributed to approximately 40,000 pharmacies, health systems, and medical providers across North America. McKesson operates through four segments: U.S. Pharmaceutical (the dominant distribution engine), Prescription Technology Solutions (pharmacy benefits technology including CoverMyMeds e-prior authorization), Medical-Surgical Solutions (physician office and extended care medical supply distribution), and International (primarily Canadian distribution through McKesson Canada).
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.